Consequently, the pursuit of reliable and effective biological markers for assessing the reaction to anti-PD-1/PD-L1 immunotherapy has become the focal point of oncoimmunology investigations in NSCLC patients. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.